CervoMed Inc. Common Stock (CRVO)
Stock · NASDAQ · Health Care
$2.24as of 10/16/2026
Price chart
Active signals
CRVO Signal Track Record
How signals performed across all stocks →What CRVO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -12.3% | 30% | September 29, 2026 |
| Bollinger Band Breakdown | 25 | -0.3% | 48% | September 15, 2026 |
| Bollinger Band Breakout | 16 | +3.5% | 56% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -2.7% | 50% | December 11, 2025 |
| Any 20-session window (baseline) | -6.1% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 15
- Website
- cervomed.com/
Fundamentals
- 1-day range
- $2.22$2.27
- Market cap
- $37.33M
- P/E (trailing)
- —
- P/E (forward)
- -1.63
- EPS (trailing)
- $-3.21
- Dividend yield
- —
- Beta
- -0.69
- Avg. volume
- 294.2K
- Dividend pay date
- December 14, 2018
How CervoMed Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
CervoMed Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRVOCervoMed Inc. Common Stock$2.24▼ 0.44%Market cap $37.33MP/E —$2.13$10
- APLMApollomics Inc. Class A Ordinary Shares$21.1▲ 0.48%Market cap $37.33MP/E —$10.01$42.12
- IXHLIncannex Healthcare Inc. Common Stock$2.82▼ 2.08%Market cap $37.21MP/E —$2.49$14.91
- VERUVeru Inc. Common Stock$2.3▼ 5.74%Market cap $37.08MP/E —$2.05$7.33
- BYSIBeyondSpring Inc. Ordinary Shares$0.559▼ 3.95%Market cap $35.77MP/E —$0.5657$2.44
- NNVCNanoViricides Inc. Common Stock$1.38▲ 0.73%Market cap $35.56MP/E —$0.85$2.23
- LTRNLantern Pharma Inc. Common Stock$0.668▲ 0.15%Market cap $35.47MP/E —$0.651$4.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRVO CervoMed Inc. Common Stock | $37.33M | — | $2.24 | ▼ 0.44% | $2.13$10 |
| APLM Apollomics Inc. Class A Ordinary Shares | $37.33M | — | $21.1 | ▲ 0.48% | $10.01$42.12 |
| IXHL Incannex Healthcare Inc. Common Stock | $37.21M | — | $2.82 | ▼ 2.08% | $2.49$14.91 |
| VERU Veru Inc. Common Stock | $37.08M | — | $2.3 | ▼ 5.74% | $2.05$7.33 |
| BYSI BeyondSpring Inc. Ordinary Shares | $35.77M | — | $0.559 | ▼ 3.95% | $0.5657$2.44 |
| NNVC NanoViricides Inc. Common Stock | $35.56M | — | $1.38 | ▲ 0.73% | $0.85$2.23 |
| LTRN Lantern Pharma Inc. Common Stock | $35.47M | — | $0.668 | ▲ 0.15% | $0.651$4.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- BOGER JOSHUA S · June 11, 2026 · Buy955.4K @ $3.14
- ZAVRL FRANK · June 8, 2026 · Grant8.2K
- Sabbagh Marwan · June 8, 2026 · Grant8.2K
- Quigley David · June 8, 2026 · Grant8.2K
- Poulton Jeffrey V. · June 8, 2026 · Grant8.2K
- Hollingsworth Jane H · June 8, 2026 · Grant8.2K
- Gregoire Sylvie · June 8, 2026 · Grant8.2K
- BOGER JOSHUA S · June 8, 2026 · Grant8.2K
- ALAM JOHN J · June 8, 2026 · Grant8.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.73M
- Total value held
- $6.82M
- Institutional holders
- 34
- Unknown739.9K
- Unknown316.2K
- Unknown208.9K
- Unknown74.4K
- Unknown63.9K
- Unknown51.7K
- Unknown38.5K
- Unknown37.5K
- Unknown30.0K
- Unknown27.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CervoMed Reports PK Data and FDA Removal of Exposure Limit
CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.
CervoMed Reports PK Data and FDA Removal of Exposure Limit. CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.